In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss how UpScriptHealth is working to increase access to legitimate weight loss medications, especially for those in underserved communities.
Peter Ax: So, if you think about our business model, what we do is we work with brands to bring medications directly to the consumer. And first of all, we increase access, because you don't have to go visit a physician or physician or directly or see a physician in physical sense of the word. You actually can literally just go online and have a real. Robust dialog with the clinician, so that increases access. And the way we serve underserved communities is by taking costs out of the system, which we do because we able to deal directly with manufacturer because we're able to hire clinicians to work online, we're able to take a lot of costs out of the system. And in addition, we have a number of instances where we work with our pharma partners to develop a couponing program for people that come online and want to buy a medication or want to talk to talk with a clinician. So, we do a lot of things to take costs out of the system, make things more efficient, more accessible, and frankly, we provide a really comfortable environment for patients to really see a clinician, they can literally do it from their home or office.
George Jones: With our partnership for Contrave that we've had since 2016 we've been able to significantly expand access to access to care for patients seeking, seeking obesity care, and seeking to take that first step in the journey to lose weight. We also offer Contrave, you know, we support both the patient's insurance to try to get it, help them get it covered by insurance, by doing the appropriate prior authorizations and getting to a pharmacy that could fill with their insurance leveraging cure X's copay card program, or we offer it for very affordable cash, cash price of $99 per month. We, you know, take a lot of pride in the in the quality of care that we're giving for these, these patients who are trying to lose weight and taking that first step on the journey.
In fact, we have, we have a partnership with a company called Trustpilot, where people do online reviews of all kinds of services, but, but we have our get contrary, our contrary weight loss platform on there. You know, I'm looking at a review from yesterday where, you know, a reviewer says she's very happy with the nurse practitioner. She's professional, knowledgeable, helpful, fully, answered all of my questions. Let the patient know that she's available for all future questions and follow up and gave her additional tips on how to you know how to be more successful on her weight loss journey. And she ends up by saying she's 100% satisfied with her visit. This is, this is what a patient wrote about our services for obesity care just yesterday. So, I just, I take a lot of pride in the care that we give. And this, this shows another patient who's excited to jump in, use Contrave to try to lose weight.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.